NCT07089173 The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
| NCT ID | NCT07089173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Shenzhen Hospital |
| Condition | Hemodynamics |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 99 participants in total. It began in 2025-08-01 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study was to compare the effect-site target concentration (including EC₅₀ and EC₉₀) of remifentanil required to suppress cardiovascular responses to tracheal intubation during anesthesia induction with etomidate combined with either lidocaine or sufentanil.
Eligibility Criteria
Inclusion Criteria: * Patients scheduled for elective surgery under general anesthesia with endotracheal intubation; * Classified as ASA physical status I-II. Exclusion Criteria: * Age \<18 years or \>65 years; * Body mass index (BMI) \>30 kg/m² or \<18.5 kg/m²; * Diagnosis of hypertension or severe cardiovascular diseases (including myocardial infarction, heart failure, atrial fibrillation, atrioventricular block, moderate-to-severe valvular diseases) or respiratory diseases (including acute exacerbation of chronic obstructive pulmonary disease, acute respiratory distress syndrome, acute asthma attack, moderate-to-severe pulmonary hypertension, severe pneumonia); * Diagnosis of obstructive sleep apnea syndrome or history of difficult intubation or preoperatively anticipated difficult airway; * Renal, hepatic or hematologic diseases; * High risk of aspiration or reflux; * Current use of analgesics for chronic pain or β-blockers for cardiovascular diseases; * Current use of psychotropic medications; * Contraindications to remifentanil or sufentanil, including: known hypersensitivity to any component of these drugs or other fentanyl analogues, current use of monoamine oxidase inhibitors, myasthenia gravis or conditions predisposing to respiratory depression, bronchial asthma or related disorders; * Contraindications to lidocaine, including: known allergy to local anesthetics, concurrent Adams-Stokes syndrome, Wolff-Parkinson-White syndrome, or severe cardiac conduction block.
Contact & Investigator
Tao Luo
PRINCIPAL INVESTIGATOR
Peking University Shenzhen Hospitai
Frequently Asked Questions
Who can join the NCT07089173 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Hemodynamics. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07089173 currently recruiting?
Yes, NCT07089173 is actively recruiting participants. Contact the research team at jzcmichael@163.com for enrollment information.
Where is the NCT07089173 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07089173 clinical trial?
NCT07089173 is sponsored by Peking University Shenzhen Hospital. The principal investigator is Tao Luo at Peking University Shenzhen Hospitai. The trial plans to enroll 99 participants.